Tagged with Suresh Mahalingam

Griffith University researchers have partnered with a leading vaccines manufacturing company based in Hyderabad, India to develop a vaccine for COVID-19.

A new Griffith University study aims to develop drugs to treat alphavirus infection such as Ross River, Chikungunya, O’nyong’nyong and Mayaro viruses which cause debilitating and chronic arthritis. Led by Professor Suresh Mahalingam, head of the Research Group for Emerging Viruses, Inflammation and Therapeutics at Menzies Health Institute Queensland, the $905,080 National Health and Medical […]

Griffith University research projects have received more than $6 million in funding from the National Health and Medical Research Council

The threat of mosquito-borne outbreaks of emerging viruses will be tackled by the newly-established Research Group for Emerging Viruses, Inflammation and Therapeutics.

By Suresh Mahalingam, Principal Research Leader, Institute for Glycomics As Zika fear rises, especially in the wake of the World Health Organization last night declaring a state of public health emergency, people are inevitably asking why we don’t have a vaccine to protect against the mosquito-borne virus. Zika is generally a mild illness, causing fever, […]